Moreover, the CXCL9, 10, or 11–CXCR3 ligand/receptor pair has also been reported to be downregulated in the metastatic and therapy-resistant tumor, which suggested the upregulation of CXCL9, 10, and 11 might be potential therapy targets for recurrent tumors (Szekely et al., 2018). This evidence concerns the gene CXCR3 and neoplasm.